Evaluation of serum PIVKA-II and MIF as diagnostic markers for HCV/HBV induced hepatocellular carcinoma

Microbial Pathogenesis

Volumn 77, Issue , 2014, Pages 31-35

  Kamel, Mahmoud M ^a,b   Saad, Mohamed F ^a   Mahmoud, Amal A ^a,c   Edries, Awatief A ^a,d   Abdel Moneim, Ahmed S ^a,e  

^a TAIF UNIVERSITY   (Saudi Arabia)

^b NATIONAL CANCER INSTITUTE   (Egypt)

^c Assiut University Faculty of Medicine   (Egypt)

^d TANTA UNIVERSITY   (Egypt)

^e Beni Suef University   (Egypt)

Author keywords

AFP; HBV; HCC; HCV; MIF; PIVKA II

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; MACROPHAGE MIGRATION INHIBITION FACTOR; AFP PROTEIN, HUMAN; BIOLOGICAL MARKER; ISOMERASE; MIF PROTEIN, HUMAN; PROTEIN PRECURSOR; PROTHROMBIN;

ADULT; AGED; ARTICLE; ASCITES; BLOOD SAMPLING; CANCER RISK; CONTROLLED STUDY; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATOSPLENOMEGALY; HUMAN; JAUNDICE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; POLYMERASE CHAIN REACTION; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; BLOOD; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; CHRONIC HEPATITIS C; COMPARATIVE STUDY; COMPLICATION; EVALUATION STUDY; PATHOLOGY; SERUM;

ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; PROTEIN PRECURSORS; PROTHROMBIN; SENSITIVITY AND SPECIFICITY; SERUM;

EID: 84908426283     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2014.10.009     Document Type: Article

References (41)

1. Song M.J., Bae S.H. Newer treatments for advanced hepatocellular carcinoma. Korean J. Intern Med. 2014, 29:149-155.
2. Tsukuma H., Hiyama T., Tanaka S., Nakao M., Yabuuchi T., Kitamura T., et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N.Engl. J. Med. 1993, 328:1797-1801.
3. El-Serag H.B. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012, 142:1264-1273. e1.
4. Michielsen P.P., Francque S.M., van Dongen J.L. Viral hepatitis and hepatocellular carcinoma. World J. Surg. Oncol. 2005, 3:27.
5. Germano D., Daniele B. Systemic therapy of hepatocellular carcinoma: current status and future perspectives. World J. Gastroenterol.: WJG 2014, 20:3087-3099.
6. Marrero J.A., Hussain H.K., Nghiem H.V., Umar R., Fontana R.J., Lok A.S. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transplant.: Official Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc. 2005, 11:281-289.
7. Sakamoto M., Mori T., Masugi Y., Effendi K., Rie I., Du W. Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma. Intervirology 2008, 51:42-45.
8. Beale G., Chattopadhyay D., Gray J., Stewart S., Hudson M., Day C., et al. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 2008, 8:200.
9. Sakamoto M., Effendi K., Masugi Y. Molecular diagnosis of multistage hepatocarcinogenesis. Jpn. J. Clin. Oncol. 2010, 40:891-896.
10. Trerotoli P., Fransvea E., Angelotti U., Antonaci G., Lupo L., Mazzocca A., et al. Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC. Mol. Cancer 2009, 8:29.
11. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. Reporting recommendations for tumor marker prognostic studies (REMARK). J.Nat. Cancer Inst. 2005, 97:1180-1184.
12. Bertino G., Demma S., Bertino N., Ardiri A. Management of hepatocellular carcinoma: an update at the start of 2014. J.Gastrointest. Dig. Syst. 2014, 4:178.
13. Marquardt J.U., Galle P.R., Teufel A. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. J.Hepatol. 2012, 56:267-275.
14. Malaguarnera G., Bertino G., Vacante M., Malaguarnera M. Hepatocellular carcinoma markers in the omics era: the glycomic analysis. Hepatobiliary Surg. Nutr. 2014, 10.3978/j.issn.2304-3881.2014.07.04.
15. Kim H.S., Park J.W., Jang J.S., Kim H.J., Shin W.G., Kim K.H., et al. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J.Clin. Gastroenterol. 2009, 43:482-488.
16. Choi J.Y., Jung S.W., Kim H.Y., Kim M., Kim Y., Kim D.G., et al. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. World J. Gastroenterol.: WJG 2013, 19:339-346.
17. Volk M.L., Hernandez J.C., Su G.L., Lok A.S., Marrero J.A. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark.: Sect. A Dis. Markers 2007, 3:79-87.
18. Zhou J., Yu L., Gao X., Hu J., Wang J., Dai Z., et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J.Clin. Oncol. 2011, 29:4781-4788.
19. Mizue Y., Ghani S., Leng L., McDonald C., Kong P., Baugh J., et al. Role for macrophage migration inhibitory factor in asthma. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:14410-14415.
20. Bucala R., Donnelly S.C. Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity 2007, 26:281-285.
21. Bosch F.X., Ribes J., Borràs J. Epidemiology of primary liver cancer. Seminars Liver Dis. 1999, 271-285. © 1999 by Thieme Medical Publishers, Inc.
22. Bressac B., Kew M., Wands J., Ozturk M. Selective G to T mutations of p 53 gene in hepatocellular carcinoma from southern Africa. Nature 1991, 350:429-431.
23. Okuda H., Nakanishi T., Takatsu K., Saito A., Hayashi N., Takasaki K., et al. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer 2000, 88:544-549.
24. Nakatsura T., Yoshitake Y., Senju S., Monji M., Komori H., Motomura Y., et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem. Biophys. Res. Commun. 2003, 306:16-25.
25. Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide T., Sata M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann. Intern Med. 1999, 131:174-181.
26. Di Bisceglie A.M. Hepatitis B and hepatocellular carcinoma. Hepatology 2009, 49:S56-S60.
27. Kiyosawa K. Trend of liver cirrhosis as precancerous lesions. Hepatol. Res. 2002, 24:40-45.
28. Takayama T., Kosuge T., Yamazaki S., Hasegawa H., Okazaki N., Takayasu K., et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990, 336:1150-1153.
29. Heyward W.L., Lanier A.P., McMahon B.J., Fitzgerald M.A., Kilkenny S., Paprocki T.R. Early detection of primary hepatocellular carcinoma. Screening for primary hepatocellular carcinoma among persons infected with hepatitis B virus. JAMA: J. Am. Med. Assoc. 1985, 254:3052-3054.
30. Liaw Y.F., Sung J.J., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N.Engl. J. Med. 2004, 351:1521-1531.
31. Chang M.H., Chen C.J., Lai M.S., Hsu H.M., Wu T.C., Kong M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N.Engl. J. Med. 1997, 336:1855-1859.
32. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
33. Zhao Y.M., Wang L., Dai Z., Wang D.D., Hei Z.Y., Zhang N., et al. Validity of plasma macrophage migration inhibitory factor for diagnosis and prognosis of hepatocellular carcinoma. Int. J. Cancer 2011, 129:2463-2472.
34. He X.-X., Yang J., Ding Y.-W., Liu W., Shen Q.-Y., Xia H.H. Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut 2006, 55:797-802.
35. Akbar S., Abe M., Murakami H., Tanimoto K., Kumagi T., Yamashita Y., et al. Macrophage migration inhibitory factor in hepatocellular carcinoma and liver cirrhosis; relevance to pathogenesis. Cancer Lett. 2001, 171:125-132.
36. Inagaki Y., Tang W., Makuuchi M., Hasegawa K., Sugawara Y., Kokudo N. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin. Liver Int. 2011, 31:22-35.
37. Bae J.S., Park S.J., Park K.B., Paik S.Y., Ryu J.K., Choi C.K., et al. Acute exacerbation of hepatitis in liver cirrhosis with very high levels of alpha-fetoprotein but no occurrence of hepatocellular carcinoma. Korean J. Intern Med. 2005, 20:80-85.
38. Daniele B., Bencivenga A., Megna A.S., Tinessa V. α-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004, 127:S108-S112.
39. Durazo F.A., Blatt L.M., Corey W.G., Lin J.H., Han S., Saab S., et al. Des-γ-carboxyprothrombin, α-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J.Gastroenterol. Hepatol. 2008, 23:1541-1548.
40. Gotoh M., Nakatani T., Masuda T., Mizuguchi Y., Sakamoto M., Tsuchiya R., et al. Prediction of invasive activities in hepatocellular carcinomas with special reference to α-fetoprotein and Des-γ-carboxyprothrombin. Jpn. J. Clin. Oncol. 2003, 33:522-526.
41. El-Assaly N.M., El Ashry N.I., Mostafa I., El Ghannam M., Attia M. Serum chromogranin-a and serum PIVKA-ii as useful complementary and diagnostic markers for HCC. Res J Med. Med. Sci. 2009, 4.